Cefepime Dihydrochloride MonohydrateCAS# 123171-59-5 |
- Alvimopan monohydrate
Catalog No.:BCC1349
CAS No.:1383577-62-5
- Alvimopan
Catalog No.:BCC1347
CAS No.:156053-89-3
- Alvimopan dihydrate
Catalog No.:BCC1348
CAS No.:170098-38-1
- JDTic
Catalog No.:BCC1670
CAS No.:361444-66-8
- ADL5859 HCl
Catalog No.:BCC1265
CAS No.:850173-95-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 123171-59-5 | SDF | Download SDF |
| PubChem ID | 9571075 | Appearance | Powder |
| Formula | C19H28Cl2N6O6S2 | M.Wt | 571.5 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | H2O : ≥ 200 mg/mL (349.96 mM) DMSO : 6 mg/mL (10.50 mM; Need ultrasonic) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;chloride;hydrate;hydrochloride | ||
| SMILES | O.[Cl-].[Cl-].CON=C(C(=O)N[C@H]1[C@H]2SCC(=C(N2C1=O)C(O)=O)C[N+]3(C)CCCC3)c4csc(N)n4.[H+] | ||
| Standard InChIKey | LRAJHPGSGBRUJN-OMIVUECESA-N | ||
| Standard InChI | InChI=1S/C19H24N6O5S2.2ClH.H2O/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11;;;/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29);2*1H;1H2/b23-12-;;;/t13-,17-;;;/m1.../s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Cefepime Dihydrochloride Monohydrate Dilution Calculator
Cefepime Dihydrochloride Monohydrate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.7498 mL | 8.7489 mL | 17.4978 mL | 34.9956 mL | 43.7445 mL |
| 5 mM | 0.35 mL | 1.7498 mL | 3.4996 mL | 6.9991 mL | 8.7489 mL |
| 10 mM | 0.175 mL | 0.8749 mL | 1.7498 mL | 3.4996 mL | 4.3745 mL |
| 50 mM | 0.035 mL | 0.175 mL | 0.35 mL | 0.6999 mL | 0.8749 mL |
| 100 mM | 0.0175 mL | 0.0875 mL | 0.175 mL | 0.35 mL | 0.4374 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Cefepime Dihydrochloride Monohydrate is a broad-spectrum cephalosporin with enhanced coverage against Gram-positive and Gram-negative bacteria. Target: Antibacterial Cefepime is an extended-spectrum parenteral cephalosporin antibiotic active in vitro against a broad spectrum of gram-positive and gram-negative aerobic bacteria. Cefepime dosing was 1-4 g/day (0.5-2.0 g twice daily) for adults; ceftazidime dosing was 1-6 g/day (0.5 g every 12 hours to 2.0 g every 8 hours). A limited number of cefepime-treated patients received 2 g every 8 hours. The median length of dosing for both cefepime and ceftazidime was 7 days [1]. Cefepime has a decreased propensity to induce beta-lactamases compared with other beta-lactam antibiotics. Cefepime has a pharmacokinetic disposition similar to that of other renally eliminated cephalosporins, with a half-life of approximately 2 hours. Cefepime has demonstrated clinical efficacy against a variety of infections, including urinary tract infections, pneumonia, and skin and skin structure infections. Cefepime is generally well tolerated [2].
References:
[1]. Neu, H.C., Safety of cefepime: a new extended-spectrum parenteral cephalosporin. Am J Med, 1996. 100(6A): p. 68S-75S.
[2]. Wynd, M.A. and J.A. Paladino, Cefepime: a fourth-generation parenteral cephalosporin. Ann Pharmacother, 1996. 30(12): p. 1414-24.
- Uncaric acid
Catalog No.:BCN6121
CAS No.:123135-05-7
- 4,8-Dihydroxyeudesm-7(11)-en-12,8-olide
Catalog No.:BCN1600
CAS No.:1231208-53-9
- BAF312 (Siponimod)
Catalog No.:BCC5114
CAS No.:1230487-00-9
- Phyltetralin
Catalog No.:BCN3051
CAS No.:123048-17-9
- Bulleyanin
Catalog No.:BCN6120
CAS No.:123043-54-9
- Azasetron HCl
Catalog No.:BCC5035
CAS No.:123040-16-4
- Azelaic Acid
Catalog No.:BCC8300
CAS No.:123-99-9
- D-erythro-Sphingosine (synthetic)
Catalog No.:BCC6729
CAS No.:123-78-4
- Anisic aldehyde
Catalog No.:BCN2618
CAS No.:123-11-5
- 4-Hydroxybenzaldehyde
Catalog No.:BCN5816
CAS No.:123-08-0
- Fmoc-Hyp(tBu)-OH
Catalog No.:BCC3256
CAS No.:122996-47-8
- RG7388
Catalog No.:BCC1895
CAS No.:1229705-06-9
- LY2835219 free base
Catalog No.:BCC1722
CAS No.:1231929-97-7
- LY2835219
Catalog No.:BCC1113
CAS No.:1231930-82-7
- VE-821
Catalog No.:BCC1207
CAS No.:1232410-49-9
- 6alpha-Hydroxytomentosin
Catalog No.:BCN7303
CAS No.:1232676-22-0
- 2'-O-Methylhelichrysetin
Catalog No.:BCN4792
CAS No.:123316-64-3
- Clofarabine
Catalog No.:BCC1078
CAS No.:123318-82-1
- AZ20
Catalog No.:BCC1389
CAS No.:1233339-22-4
- Dipsacobioside
Catalog No.:BCN6552
CAS No.:123350-57-2
- kb NB 142-70
Catalog No.:BCC1675
CAS No.:1233533-04-4
- CAY10650
Catalog No.:BCC4178
CAS No.:1233706-88-1
- Methyl 4-caffeoylquinate
Catalog No.:BCN3442
CAS No.:123372-74-7
- ELR510444
Catalog No.:BCC6418
CAS No.:1233948-35-0
Stability of cefepime dihydrochloride monohydrate in solid state.[Pubmed:12403297]
Acta Pol Pharm. 2002 Jul-Aug;59(4):243-6.
The pseudo first-order rate constants and thermodynamic parameters for the decomposition of cefepime in solid state in absence of humidity and at a relative humidity of 76.4% were calculated. The effect of humidity on the stability of Cefepime Dihydrochloride Monohydrate in the humidity range 25.0%-76.4% at 358 K is described by the equation ln ki = (0.031 +/- 0.0043) x RH% - 10.08 +/- 0.22.
Identification and characterization of new degradation products of cefepime dihydrochloride monohydrate drug substance during stress stability studies.[Pubmed:20953052]
Anal Sci. 2010;26(10):1081-6.
The degradation products of Cefepime dihydrochloride that emerged throughout stress stability studies have been determined, identified and characterized. The two new impurities were detected by gradient reverse-phase high performance liquid chromatography (HPLC), and Impurity-I was formed in the range from 0.2 to 11.0% and Impurity-II range from 0.2 to 3.5%. These impurities have been identified by LC/MS, and were not reported in the literature. These impurities were synthesized, isolated and characterized. Based on the spectral data, the impurities were named (6R,7R)-7-[(Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetamido]-3-[(1-methyl-1- pyrrolidinium)methyl]-3-cephem-4-carboxylate-1-oxide (Impurity-I); (2RS)-2[[(Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetamido]-methyl]-1,2,5,7-t etrahydro-7-oxo-4H-furo[3,4-d][1,3]thiazine (Impurity-II). The structures were established unambiguously by independent synthesis and co-injection in HPLC to confirm the retention times and relative retention times. The structural elucidation of these impurities by spectral data ((1)H NMR, (13)C NMR, 2D-NMR (COSY, HSQC and HMBC), LC/MS, TOF-MS, elemental analysis and IR), synthesis, isolation and the formation of these impurities are discussed in detail.
